Entrada Therapeutics (TRDA) Non-Current Deffered Revenue (2021)
Entrada Therapeutics (TRDA) posted quarterly Non-Current Deffered Revenue of $396000.0 for Q4 2021, up 16.81% quarter-over-quarter from $339000.0 in Q3 2021.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Non-Current Deffered Revenue (2021) Analysis & Trends
Entrada Therapeutics' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $396000.0 for Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue changed N/A year-over-year to $396000.0; the TTM figure through Dec 2021 stood at $396000.0 (changed N/A YoY), while the FY2021 annual figure was $396000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2021 stood at $396000.0, up from $339000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $396000.0 in Q4 2021, with the low at $339000.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Entrada Therapeutics | 297.03 Mn | 297.03 Mn | - | - |